Akebia Therapeutics, Inc. - 8-K Summary
Business Context and Reporting Period
This Form 8-K Current Report was filed by Akebia Therapeutics, Inc. on June 11, 2019, covering events occurring on June 6, 2019, and June 10, 2019. The report details the results of the Company's 2019 Annual Meeting of Stockholders and a subsequent departure from the Board of Directors.
Key Financial Metrics
The filing text does not provide revenue, profit, cash flow, margins, debt, or liquidity figures. This report focuses on corporate governance and stockholder actions rather than financial performance.
Material Changes and Corporate Actions
- Board Departure: Scott A. Canute, a Class I Director, resigned from the Board effective June 10, 2019, for personal reasons. The resignation was not due to any disagreement with the Company. Mr. Canute entered into a consulting agreement with the Company effective on the same date.
- Annual Meeting Results: The 2019 Annual Meeting was held on June 6, 2019. Stockholders approved three key proposals:
- Election of three Class II directors: John P. Butler, Michael T. Heffernan, and Jodie P. Morrison.
- Ratification of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2019.
- Approval of the Amended and Restated 2014 Employee Stock Purchase Plan.
Voting Results
| Proposal / Director | Votes For | Votes Against / Withheld | Abstentions / Broker Non-Votes |
|---|---|---|---|
| John P. Butler (Director) | 73,296,079 | 6,897,477 (Withheld) | 23,216,129 (Broker Non-Votes) |
| Michael T. Heffernan (Director) | 78,446,359 | 1,747,197 (Withheld) | 23,216,129 (Broker Non-Votes) |
| Jodie P. Morrison (Director) | 76,795,043 | 3,398,513 (Withheld) | 23,216,129 (Broker Non-Votes) |
| Ratify Ernst & Young LLP | 100,573,965 | 1,994,508 (Against) | 841,212 (Abstentions) |
| Approve ESPP | 77,488,178 | 2,529,083 (Against) | 176,295 (Abstentions) / 23,216,129 (Broker Non-Votes) |
Guidance, Outlook, and Risks
The filing does not contain financial guidance, management commentary on future outlook, or specific risk factors. The only noted contingency is the transition of Mr. Canute from a director to a consultant.
Key Facts for Investor Verification
- Verify the terms of the consulting agreement entered into with Scott A. Canute following his resignation.
- Review the full text of the Amended and Restated 2014 Employee Stock Purchase Plan (Exhibit 99.1) for specific terms.
- Confirm the composition of the Board of Directors following the election of the new Class II directors.